Literature DB >> 11916930

Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes : the Leiden 85-Plus Study.

Eric van Exel1, Jacobijn Gussekloo, Anton J M de Craen, Marijke Frölich, Annetje Bootsma-Van Der Wiel, Rudi G J Westendorp.   

Abstract

It has been suggested that the metabolic syndrome and type 2 diabetes are manifestations of the inflammatory host response. This host response is orchestrated by the production of pro- and anti-inflammatory cytokines that are under genetic control. We therefore hypothesized that a low production capacity of interleukin-10 (IL-10), a centrally operating cytokine with strong anti-inflammatory properties, associates with the metabolic syndrome and type 2 diabetes in old age. In the current study, 599 inhabitants of the city of Leiden, age 85 years, were visited at their place of residence. The production capacity of the anti-inflammatory cytokine IL-10 was assessed in a whole-blood assay in which lipopolysaccharide was used as a stimulus. Serum concentrations of lipids, lipoproteins, glucose, and HbA(1c) were determined, and a history of type 2 diabetes was obtained. Serum concentrations of total cholesterol, LDL cholesterol, triglycerides, glucose, and HbA(1c) gradually decreased over strata representing higher IL-10 production capacity, whereas the concentration of HDL cholesterol gradually increased (all P < 0.01). The odds ratio for type 2 diabetes was 2.7 (95% confidence interval 1.5-4.9) when subjects with the lowest IL-10 production capacity were compared with those with the highest IL-10 production capacity. These findings showed that low IL-10 production capacity (i.e., a pro-inflammatory response) is associated with the metabolic syndrome and type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11916930     DOI: 10.2337/diabetes.51.4.1088

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  100 in total

1.  Men Have a Stronger Monocyte-Derived Cytokine Production Response upon Stimulation with the Gram-Negative Stimulus Lipopolysaccharide than Women: A Pooled Analysis Including 15 Study Populations.

Authors:  Karel G M Beenakker; Rudi G J Westendorp; Anton J M de Craen; Sijia Chen; Yotam Raz; Bart E P B Ballieux; Rob G H H Nelissen; Alexander F L Later; Tom W Huizinga; Pieternella E Slagboom; Dorret I Boomsma; Andrea B Maier
Journal:  J Innate Immun       Date:  2019-06-21       Impact factor: 7.349

2.  Low interleukin-10 production is associated with diabetes in HIV-infected patients undergoing antiviral therapy.

Authors:  Daria Trabattoni; Monica Schenal; Miriam Cesari; Eleonora Castelletti; Michela Pacei; Billi Goldberg; Andrea Gori; Mario Clerici
Journal:  Med Microbiol Immunol       Date:  2006-01-26       Impact factor: 3.402

Review 3.  B Lymphocytes in obesity-related adipose tissue inflammation and insulin resistance.

Authors:  Daniel A Winer; Shawn Winer; Melissa H Y Chng; Lei Shen; Edgar G Engleman
Journal:  Cell Mol Life Sci       Date:  2013-10-15       Impact factor: 9.261

4.  Proteomic Insight Reveals Elevated Levels of Albumin in Circulating Immune Complexes in Diabetic Plasma.

Authors:  Shweta Bhat; Mashanipalya G Jagadeeshaprasad; Yugendra R Patil; Mahemud L Shaikh; Bhaskaran S Regin; Viswanathan Mohan; Ashok P Giri; Muthuswamy Balasubramanyam; Ramanamurthy Boppana; Mahesh J Kulkarni
Journal:  Mol Cell Proteomics       Date:  2016-04-07       Impact factor: 5.911

5.  Functionalized scaffold-mediated interleukin 10 gene delivery significantly improves survival rates of stem cells in vivo.

Authors:  Carolyn Holladay; Karen Power; Michael Sefton; Timothy O'Brien; William M Gallagher; Abhay Pandit
Journal:  Mol Ther       Date:  2011-01-25       Impact factor: 11.454

6.  Serum levels of interleukin 10 (IL-10) in patients with type 2 diabetes.

Authors:  N Yaghini; M Mahmoodi; Gh R Asadikaram; Gh H Hassanshahi; H Khoramdelazad; M Kazemi Arababadi
Journal:  Iran Red Crescent Med J       Date:  2011-10-01       Impact factor: 0.611

7.  Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial.

Authors:  Fernanda M Consolim-Colombo; Carine T Sangaleti; Fernando O Costa; Tercio L Morais; Heno F Lopes; Josiane M Motta; Maria C Irigoyen; Luiz A Bortoloto; Carlos Eduardo Rochitte; Yael Tobi Harris; Sanjaya K Satapathy; Peder S Olofsson; Meredith Akerman; Sangeeta S Chavan; Meggan MacKay; Douglas P Barnaby; Martin L Lesser; Jesse Roth; Kevin J Tracey; Valentin A Pavlov
Journal:  JCI Insight       Date:  2017-07-20

8.  Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002.

Authors:  C Herder; J Baumert; B Thorand; W Koenig; W de Jager; C Meisinger; T Illig; S Martin; H Kolb
Journal:  Diabetologia       Date:  2006-03-11       Impact factor: 10.122

9.  Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients.

Authors:  Wai-Johnn Sam; Christine E Chamberlain; Su-Jun Lee; Joyce A Goldstein; Douglas A Hale; Roslyn B Mannon; Allan D Kirk; Yuen Yi Hon
Journal:  Transplantation       Date:  2012-11-15       Impact factor: 4.939

10.  Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle.

Authors:  Eun-Gyoung Hong; Hwi Jin Ko; You-Ree Cho; Hyo-Jeong Kim; Zhexi Ma; Tim Y Yu; Randall H Friedline; Evelyn Kurt-Jones; Robert Finberg; Matthew A Fischer; Erica L Granger; Christopher C Norbury; Stephen D Hauschka; William M Philbrick; Chun-Geun Lee; Jack A Elias; Jason K Kim
Journal:  Diabetes       Date:  2009-08-18       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.